Compare KB Financial Group, Inc. (KB) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? KB Financial Group, Inc. trades at $115.32 (market cap $41.70B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: KB Financial Group, Inc. is far larger — about 5.7× Spyre Therapeutics Inc. Common Stock's market cap, and KB Financial Group, Inc. pays a 2.83% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| KB | SYRE | |
|---|---|---|
Market Cap | $41.70B | $7.35B |
Volume | 251,007 | 1,624,631 |
Sector | Financials | Health |
52-Week High | $132.88 | $108.92 |
52-Week Low | $80.15 | $22.18 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $213.39T | $6.35B |
Dividend Yield | 2.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial trades at $121.44, down 0.44% today, with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $3.79 beating expectations of $3.51. Revenue growth continues from $21.23T in 2025 to projected $22.37T in 2026, while net margins improved to 27.47%. Analyst consensus shows 33% buy ratings with 67% hold, indicating cautious optimism despite technical weakness.
KB presents a value opportunity with attractive valuation metrics including P/E of 9.24 and P/B of 0.9, trading below book value. The main risks include South Korean economic exposure and banking sector volatility, while catalysts include continued earnings momentum and institutional accumulation as seen in Nykredit's recent $10.9M position acquisition.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
